13F filer · CIK 1652044 ↗

Alphabet Inc.

You are looking at Q3 2023. See the latest, Q2 2026 →

Reported value

$1.56B

−16% on the quarter before

Positions

3 new · 5 sold out

Top 10

82.5%

of the value

Est. gain

−$214.8M

on stocks held all quarter

Est. return

−12.9%

on those stocks since Q2 2023

Filed

Nov 13, 2023

On SEC EDGAR ↗

Positions as of Sep 30, 2023, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2023. Striped tiles are options.

UiPath15%CrowdStrike14%

Verve Therapeutics Inc9.0%

Gitlab Inc7.7%

Prime Medicine Inc7.3%

Eqrx Inc6.8%

Arm Holdings Plc6.7%

Planet Labs Pbc5.3%

Snowflake5.3%

Oscar Health Inc5.2%

Freshworks Inc5.2%

Dexcom Inc3.9%

21 others1.8%

Desktop Metal Inc1.0%

0.8%

0.7%

0.6%

0.5%

UiPath15%CrowdStrike14%

Verve Therapeutics Inc9.0%

Gitlab Inc7.7%

Prime Medicine Inc7.3%

Eqrx Inc6.8%

Arm Holdings Plc6.7%

Planet Labs Pbc5.3%

Snowflake5.3%

Oscar Health Inc5.2%

Freshworks Inc5.2%

Dexcom Inc3.9%

21 others1.8%

Desktop Metal Inc1.0%

0.8%

0.7%

0.6%

0.5%

Largest buys

Since Q2 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Arm Holdings Plc~$104.9MNew · 0.0% → 6.7%+1,960,784 shares
Dianthus Therapeutics Inc~$2.9MNew · 0.0% → 0.2%+208,697 shares
Neumora Therapeutics Inc.~$2.8MNew · 0.0% → 0.2%+199,608 shares

Largest sells

Since Q2 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Oscar Health Inc~$53.3MCut · 10.4% → 5.2%−9,565,490 shares
Dexcom Inc~$52.1MCut · 8.4% → 3.9%−557,952 shares
Lyft Inc~$35.5MSold out · 1.9% → 0.0%−3,702,054 shares
Decibel Therapeutics Inc.~$6.3MSold out · 0.3% → 0.0%−1,636,258 shares
Robinhood~$6.1MSold out · 0.3% → 0.0%−612,214 shares
Magenta Therapeutics Inc.~$2.5MSold out · 0.1% → 0.0%−3,339,138 shares
Oportun Finl Corp~$565,884Sold out · 0.0% → 0.0%−94,788 shares

Holdings

As of Sep 30, 2023. Changes are in shares against Jun 30, 2023, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	UiPathCL A · shares 0% · price +3.3%	15.5%	12.5%	$240.7M	14.1M	0%	$17.11	$16.57	+3.3%	+$7.6M
2	CrowdStrikeCL A · shares 0% · price +14.0%	13.8%	10.1%	$214.9M	1.3M	0%	$167.38	$146.87	+14.0%	+$26.3M
3	Verve Therapeutics IncCOM · shares 0% · price −29.3%	9.0%	10.6%	$139.9M	10.5M	0%	$13.26	$18.75	−29.3%	−$57.9M
4	Gitlab IncCLASS A COM · shares 0% · price −11.5%	7.7%	7.3%	$119.7M	2.6M	0%	$45.22	$51.11	−11.5%	−$15.6M
5	Prime Medicine IncCOM · shares 0% · price −34.9%	7.3%	9.3%	$113.2M	11.9M	0%	$9.54	$14.65	−34.9%	−$60.6M
6	Eqrx IncCOM · shares 0% · price +19.4%	6.8%	4.8%	$105.8M	47.7M	0%	$2.22	$1.86	+19.4%	+$17.2M
7	Arm Holdings PlcSPONSORED ADR · shares New	6.7%	—	$104.9M	2.0M	New	$53.52	—	—	—
8	Planet Labs PbcCOM CL A · shares 0% · price −19.3%	5.3%	5.5%	$83.1M	31.9M	0%	$2.60	$3.22	−19.3%	−$19.8M
9	SnowflakeCL A · shares 0% · price −13.2%	5.3%	5.1%	$81.8M	535,604	0%	$152.77	$175.98	−13.2%	−$12.4M
10	Oscar Health IncCL A · shares −40% · price −30.9%	5.2%	10.4%	$80.6M	14.5M	−40%	$5.57	$8.06	−30.9%	−$36.0M
11	Freshworks IncCLASS A COM · shares 0% · price +13.3%	5.2%	3.8%	$80.4M	4.0M	0%	$19.92	$17.58	+13.3%	+$9.4M
12	Dexcom IncCOM · shares −46% · price −27.4%	3.9%	8.4%	$61.1M	654,854	−46%	$93.30	$128.51	−27.4%	−$23.1M
13	Desktop Metal IncCOM CL A · shares 0% · price −17.5%	1.0%	1.1%	$16.1M	11.0M	0%	$1.46	$1.77	−17.5%	−$3.4M
14	Relay Therapeutics IncCOM · shares 0% · price −33.0%	0.85%	1.1%	$13.2M	1.6M	0%	$8.41	$12.56	−33.0%	−$6.5M
15	Sana Biotechnology IncCOM · shares 0% · price −35.1%	0.70%	0.90%	$10.9M	2.8M	0%	$3.87	$5.96	−35.1%	−$5.9M
16	Invivyd IncCOM · shares 0% · price +61.9%	0.62%	0.32%	$9.7M	5.7M	0%	$1.70	$1.05	+61.9%	+$3.7M
17	Rapt Therapeutics IncCOM · shares 0% · price −11.1%	0.58%	0.54%	$9.0M	540,270	0%	$16.62	$18.70	−11.1%	−$1.1M
18	Lyell Immunopharma IncCOM · shares 0% · price −53.8%	0.55%	1.0%	$8.6M	5.9M	0%	$1.47	$3.18	−53.8%	−$10.0M
19	Beam Therapeutics IncCOM · shares 0% · price −24.7%	0.50%	0.55%	$7.7M	321,604	0%	$24.05	$31.93	−24.7%	−$2.5M
20	Illumina IncCOM · shares 0% · price −26.8%	0.47%	0.54%	$7.3M	53,470	0%	$137.28	$187.49	−26.8%	−$2.7M
21	Monte Rosa Therapeutics IncCOM · shares 0% · price −30.1%	0.45%	0.54%	$7.0M	1.5M	0%	$4.79	$6.85	−30.1%	−$3.0M
22	Benson Hill IncCOMMON STOCK · shares 0% · price −74.6%	0.33%	1.1%	$5.1M	15.4M	0%	$0.330	$1.30	−74.6%	−$14.9M
23	Vaccitech PlcADS · shares 0% · price +50.0%	0.30%	0.17%	$4.7M	1.5M	0%	$3.09	$2.06	+50.0%	+$1.6M
24	Vera Therapeutics IncCL A · shares 0% · price −14.6%	0.27%	0.26%	$4.1M	301,580	0%	$13.71	$16.05	−14.6%	−$705,698
25	Dianthus Therapeutics IncCOM · shares New	0.18%	—	$2.9M	208,697	New	$13.67	—	—	—
	Total · 45 positions	100%		$1.56B						−$214.8M

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q2 2023 to Q3 2023: 42 stocks held throughout, down $214.8M (−12.9%).

CrowdStrike+$26.3M+14%
Eqrx Inc+$17.2M+19%
Freshworks Inc+$9.4M+13%
UiPath+$7.6M+3%
Invivyd Inc+$3.7M+62%
Planet Labs Pbc−$19.8M−19%
Dexcom Inc−$23.1M−27%
Oscar Health Inc−$36.0M−31%
Verve Therapeutics Inc−$57.9M−29%
Prime Medicine Inc−$60.6M−35%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$110.00B$55.00B$0

Q1 201642 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 7, 2026	$99.08B+2,367%	28	SEC ↗
Q1 2026	May 8, 2026	$4.02B+56%	26	SEC ↗
Q4 2025	Feb 13, 2026	$2.58B+7%	29	SEC ↗
Q3 2025	Nov 7, 2025	$2.41B+13%	37	SEC ↗
Q2 2025	Aug 1, 2025	$2.14B+35%	36	SEC ↗
Q1 2025	May 2, 2025	$1.58B−8%	40	SEC ↗
Q4 2024	Feb 7, 2025	$1.72B−7%	40	SEC ↗
Q3 2024	Nov 8, 2024	$1.84B−7%	42	SEC ↗
Q2 2024	Aug 2, 2024	$1.97B−21%	42	SEC ↗
Q1 2024	May 3, 2024	$2.51B+17%	43	SEC ↗
Q4 2023	Feb 9, 2024	$2.16B+39%	44	SEC ↗
Q3 2023	Nov 13, 2023	$1.56B−16%	45	SEC ↗
Q2 2023	Aug 4, 2023	$1.86B+3%	47	SEC ↗
Q1 2023	May 11, 2023	$1.80B+5%	49	SEC ↗
Q4 2022	Feb 14, 2023	$1.72B−12%	51	SEC ↗
Q3 2022	Nov 15, 2022	$1.96B+6%	49	SEC ↗
Q2 2022	Nov 15, 2022	$1.84B−40%	55	SEC ↗
Q1 2022	Nov 15, 2022	$3.08B−26%	60	SEC ↗
Q4 2021	Nov 15, 2022	$4.14B−2%	58	SEC ↗
Q3 2021	Nov 15, 2022	$4.22B−14%	43	SEC ↗
Q2 2021	Nov 15, 2022	$4.91B+98%	36	SEC ↗
Q1 2021	Nov 15, 2022	$2.48B+19%	32	SEC ↗
Q4 2020	Nov 15, 2022	$2.08B−2%	31	SEC ↗
Q3 2020	Nov 15, 2022	$2.13B−2%	24	SEC ↗
Q2 2020	Nov 15, 2022	$2.17B+42%	24	SEC ↗
Q1 2020	Nov 15, 2022	$1.52B−8%	25	SEC ↗
Q4 2019	Nov 15, 2022	$1.65B−50%	24	SEC ↗
Q3 2019	Nov 15, 2022	$3.33B−37%	24	SEC ↗
Q2 2019	Nov 15, 2022	$5.27B+172%	22	SEC ↗
Q1 2019	Nov 15, 2022	$1.94B+129%	17	SEC ↗
Q4 2018	Nov 15, 2022	$845.8M−19%	17	SEC ↗
Q3 2018	Nov 15, 2022	$1.04B−12%	17	SEC ↗
Q2 2018	Nov 15, 2022	$1.19B+94%	17	SEC ↗
Q1 2018	Nov 15, 2022	$614.8M+67%	11	SEC ↗
Q4 2017	Nov 15, 2022	$368.6M+7%	8	SEC ↗
Q3 2017	Nov 15, 2022	$344.0M−1%	4	SEC ↗
Q2 2017	Nov 15, 2022	$347.4M+10%	4	SEC ↗
Q1 2017	Nov 15, 2022	$316.8M+8%	3	SEC ↗
Q4 2016	Nov 15, 2022	$292.8M+6%	2	SEC ↗
Q3 2016	Nov 15, 2022	$275.2M+31%	2	SEC ↗
Q2 2016	Nov 15, 2022	$209.8M−14%	3	SEC ↗
Q1 2016	Nov 15, 2022	$242.9M	5	SEC ↗